BIO-Europe Spring® 2014: Dealmaking strategies around orphan diseases

March 27, 2014
In recent years, orphan diseases have turned from ""do not touch"" to everyone's darling. With vast unmet medical needs, improving understanding of diseases, smaller regulatory hurdles and aggressive pricing, both pharma and biotechs see the potential in indications with very limited patient populations. Do orphan drug developers need partners? Or does having a clearly defined potential market make it much easier for biotech companies to go it alone? For more information on BIO-Europe Spring, visit our webpage: http://www.ebdgroup.com/bes/index.php Please view the rest of the video at http://www.partnering360.com/insight/showroom/id/487
Previous Video
BIO-Europe Spring 2014: Interview with Mark Velleca, The Leukemia & Lymphoma Society
BIO-Europe Spring 2014: Interview with Mark Velleca, The Leukemia & Lymphoma Society

Mark Velleca of The Leukemia & Lymphoma Society (LLS) wants new therapies now for life threatening hematolo...

Next Video
BIO-Europe Spring® 2014: Go big or go home: When to go against the trends in R&D and dealmaking
BIO-Europe Spring® 2014: Go big or go home: When to go against the trends in R&D and dealmaking

Every pharma company boasts about being innovation-driven, yet most of their R&D targets and approaches are...